IDEXX Laboratories, Inc. vs Southwest Airlines Co — how do they compare? IDEXX Laboratories, Inc. trades at $518 (market cap $40.43B), while Southwest Airlines Co trades at $41.66 (market cap $20.23B). The key difference: IDEXX Laboratories, Inc. is the larger of the two by market cap, and Southwest Airlines Co pays a 1.74% dividend while IDEXX Laboratories, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold IDEXX Laboratories, Inc. for 46 Days and Southwest Airlines Co for 65 Days on average.
| IDXX | LUV | |
|---|---|---|
Market Cap | $40.43B | $20.23B |
Volume | 692,164 | 14,560,422 |
Sector | Health | Industrials |
52-Week High | $766.68 | $54.80 |
52-Week Low | $504.70 | $29.67 |
Typical Hold Time | 46 Days | 65 Days |
Enterprise Value | $41.32B | $23.33B |
Dividend Yield | — | 1.74% |
Signals from Pluang's Aura AI — not financial advice
IDEXX Laboratories (IDXX) trades at $513.14, up 1.28% with strong fundamentals including 25.03% net income margin and 74.21% ROE. The stock shows bearish technical signals but maintains consistent earnings beats and analyst consensus of $665 price target. Recent acquisition of CoVetAI expands AI capabilities in veterinary workflow intelligence, supporting long-term growth framework.
Outlook remains positive with revenue growth accelerating to $4.3B in 2025 and projected $4.6B in 2026. Key risks include foreign exchange headwinds and weaker U.S. veterinary visits. The 56.5% buy rating from analysts suggests continued confidence in the company's diagnostic innovation pipeline and recurring revenue economics.
Southwest Airlines (LUV) trades at $41.36, down 0.86% on the day, with a mixed technical picture showing bearish moving averages but neutral oscillators. Fundamentally, the company reported revenue of $28.06B in 2025 with a net income margin of 2.78%, while valuation ratios like P/E of 25.85 and P/S of 0.72 suggest moderate pricing. Recent earnings have been volatile, with a significant beat in Q2 2026 but a miss in Q1 2026, and the upcoming Q3 2026 results on October 21, 2026, are highly anticipated amid a commercial transformation driving record unit revenue.
The outlook for LUV is cautiously optimistic, with analyst consensus pointing to a $49.61 price target and 42% buy ratings, but risks include high fuel costs, competitive pressures from rivals like United and American, and macroeconomic volatility. Investment opportunity lies in the successful execution of new fare structures and ancillary services, projected to boost EBIT, though bearish technical signals and net cash outflows require careful monitoring for sustained shareholder value.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →Southwest Airlines is the largest domestic carrier in the United States, as measured by the number of originating passengers boarded. Southwest operates over 700 aircraft in an all-Boeing 737 fleet. Despite expanding into longer routes and business travel, the airline still specializes in short-haul leisure flights, using a point-to-point network. Southwest operates a low-cost carrier business model.
Read more on LUV →